secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001437749-25-033616
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q3 product sales $22.5M (+129% YoY), non-GAAP EPS $0.04, ET-600 PDUFA Feb 2026
--------------------------------------------------------------------------------

- Product sales of $22.5M, up 129% YoY; 19th consecutive quarter of sequential growth.
- GAAP EPS loss $0.07; non-GAAP diluted EPS $0.04; Adjusted EBITDA $2.9M.
- ET-600 NDA accepted with PDUFA date February 25, 2026; launch production scheduled.
- INCRELEX largest revenue contributor; GALZIN exceeded year-end target of 200 active patients.
- Generated $12.0M cash from operations; ending cash balance $37.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/0001437749-25-033616-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925033616/eton20250819_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033616

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer